Compare Nutanix Inc (NTNX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs TG Therapeutics Inc — how do they compare? Nutanix Inc trades at $54 (market cap $14.90B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Nutanix Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| NTNX | TGTX | |
|---|---|---|
Market Cap | $14.90B | $8.26B |
Sector | Technology | Health |
52-Week High | $81.12 | $59.06 |
52-Week Low | $34.41 | $26.39 |
Enterprise Value | $14.41B | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
